Cellectar Biosciences, Inc.
CLRB
$0.2515
$0.00732.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 119.26% | 143.88% | 87.17% | 34.03% | 10.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.90% | 52.45% | 47.86% | 34.67% | 35.22% |
| Operating Income | -32.90% | -52.45% | -47.86% | -34.67% | -35.22% |
| Income Before Tax | -3.93% | -10.61% | -48.74% | -89.29% | -34.47% |
| Income Tax Expenses | 210.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -4.23% | -10.62% | -48.83% | -89.45% | -34.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.23% | -10.62% | -48.83% | -89.45% | -34.53% |
| EBIT | -32.90% | -52.45% | -47.86% | -34.67% | -35.22% |
| EBITDA | -32.80% | -52.30% | -47.74% | -34.54% | -35.24% |
| EPS Basic | 62.31% | 55.84% | 22.37% | 7.20% | 20.58% |
| Normalized Basic EPS | 62.40% | 55.81% | 22.39% | 7.24% | 20.60% |
| EPS Diluted | 57.19% | 51.26% | 18.27% | 7.10% | 20.50% |
| Normalized Diluted EPS | 62.55% | 55.94% | 22.42% | 7.24% | 20.60% |
| Average Basic Shares Outstanding | 199.56% | 173.44% | 137.59% | 100.67% | 73.21% |
| Average Diluted Shares Outstanding | 203.82% | 178.21% | 141.81% | 100.67% | 73.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |